Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank

Ashish M. Kamat(The University of Texas MD Anderson Cancer Center), Jonathan E. Rosenberg(Memorial Sloan Kettering Cancer Center), Wassim Kassouf(McGill University), Stephanie Chisolm(Bladder Cancer Advocacy Network), James H. Doroshow(National Cancer Institute), Siamak Daneshmand(Unknown), Jason A. Efstathiou(Massachusetts General Hospital), Diane Zipursky Quale, Jay B. Shah(The University of Texas MD Anderson Cancer Center), Stephen B. Williams(Cedars-Sinai Medical Center), Gopa Iyer(Memorial Sloan Kettering Cancer Center), Trinity J. Bivalacqua(University of Pennsylvania), John A. Taylor(UConn Health), Piyush K. Agarwal(University of Chicago), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai)
Bladder Cancer
April 2, 2016
10.3233/blc-169007
Cited by 4

Related Papers

Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress
|New England Journal of Medicine|2005|3.1k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k